Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Godaddy Inc (GDDY) vs Novavax Inc (NVAX) Price & Performance

Godaddy IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Godaddy Inc vs Novavax Inc — how do they compare? Godaddy Inc trades at $90.75 (market cap $11.49B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Godaddy Inc is far larger — about 8.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.

GDDYNVAX
Market Cap
$11.49B$1.31B
Sector
TechnologyHealth
52-Week High
$148.88$11.19
52-Week Low
$75.07$6.22
Enterprise Value
$14.18B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Godaddy Inc

GoDaddy (GDDY) trades at $91.81, up 0.34% today, with a bearish technical signal but strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and a P/E of 13.48, indicating potential undervaluation. However, recent news highlights multiple securities investigations, creating investor uncertainty. Revenue growth is steady, projected at $5.1B for 2026, while cash flow trends improved in 2024 before a slight dip in 2025.

The stock presents a mixed outlook: analyst consensus is bullish with a $112.13 price target (21 buys, 15 holds, 1 sell), but technical indicators and legal risks weigh on near-term sentiment. Key opportunities include consistent earnings outperformance and solid profitability, while risks involve ongoing legal probes and high debt levels. Investors should balance fundamental strength against headline volatility.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX